Today: 1 July 2026
Rocket Lab stock slides again as RKLB pulls back from January highs
2 February 2026
1 min read

Rocket Lab stock slides again as RKLB pulls back from January highs

New York, Feb 2, 2026, 14:48 EST — Regular session

Rocket Lab shares dropped over 5% Monday afternoon, deepening a steep retreat from their January peak as investors reconsidered the company’s growth prospects. By 2:28 p.m. ET, the stock slid 5.35% to $75.79, after dipping to $75.17—roughly 24% shy of its Jan. 16 high of $99.58.

This move is significant as Rocket Lab has become a high-expectation stock, prone to sharp swings on policy news and timing delays. Its recent volatility has drawn heavy interest from both bulls and bears.

Investors are weighing how much of Rocket Lab’s backlog depends on government contracts and how fast it can expand beyond its Electron rocket into more lucrative areas. That discussion is growing louder as the stock loses steam.

Talk around NASA’s Mars Sample Return mission is causing fresh uncertainty. The plan aims to retrieve Martian samples gathered by the Perseverance rover and bring them back to Earth. But a Nasdaq.com article published late Saturday reported that U.S. Congress has pulled funding for the current program, despite Rocket Lab’s $4 billion proposal.

The valuation has intensified the response. Barron’s noted Rocket Lab is currently trading at roughly 45 times its projected sales over the next 12 months, with analysts not expecting a full-year profit until 2027. That leaves scant margin for error.

Rocket Lab has maintained its launch rhythm with Electron. Last week, it completed its 81st Electron mission from New Zealand, putting a satellite into orbit for the Korea Advanced Institute of Science and Technology. CEO Sir Peter Beck described the two launches within eight days as “a strong start to the year.” GlobeNewswire

Investors are zeroed in on Neutron, Rocket Lab’s bigger rocket aimed at taking on SpaceX’s Falcon 9. Space.com reports the “Hungry Hippo” payload fairing—Neutron’s satellite-protecting shell—has touched down at Virginia’s Mid-Atlantic Regional Spaceport. But a failed pressure test on the main stage has thrown the first-flight schedule into doubt.

But when a stock is priced for speed, even minor setbacks can sting. Any hiccup in Neutron’s development, a slowdown in launches, or conservative forecasts on space systems demand could weigh on the shares.

Rocket Lab is set to release its Q4 and full-year 2025 results after the U.S. market closes on Feb. 26, with a conference call scheduled for 5 p.m. ET.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Abivax Kicks Off $600M ADS Offering in U.S.
    June 30, 2026, 6:16 PM EDT. Abivax SA, the immune therapeutics biotech, said it's starting a public offering of about $600 million in American Depositary Shares in the U.S. The new ADSs, listed on Euronext Paris and Nasdaq under ABVX, are being sold under the Securities Act of 1933. Underwriters could take up to 15% more ADSs if they want. The deal is a capital increase without preferential subscription rights, approved by shareholders in May 2026. Pricing and size aren't set yet and still depend on market conditions. Bookbuilding comes first. Euronext Paris will halt ordinary share trading July 1, 2026, before Nasdaq resumes trading of the ADSs later that day.
Johnson & Johnson stock rises as new Erleada survival data lands
Previous Story

Johnson & Johnson stock rises as new Erleada survival data lands

Amphenol stock price steadies near $145 after earnings whipsaw as traders eye Tuesday’s U.S. shutdown vote
Next Story

Amphenol stock price steadies near $145 after earnings whipsaw as traders eye Tuesday’s U.S. shutdown vote

Go toTop